EDTA 2008
EDTA Conference
Stockholm, 10-13 May 2008
Dr Bruce Spinowitz, USA
Poster SP385, XLV ERA-EDTA Congress in Stockholm,
May 10–13, 2008
“Irrespective of route of administration MIRCERA both IV and SC was able to maintain haemoglobin at a steady level.”
 Download EDTA Poster SP385 "C.E.R.A. maintains stable haemoglobin levels in dialysis patients regardless of administration route (IV or SC)" |
 |
Video Selector
Once Monthly C.E.R.A. provides stable Hb levels in CKD patients on dialysis following direct switch from shorter acting ESAs (Poster number SA:PO2669)
- Dr Danilo Fliser
- ASN 2008
The safety profiles of ESAs at different hemoglobin levels (Poster number SA:PO2670)
- Dr Robert Provenzano
- ASN 2008
Erythrocyte survival, biology of erythropoiesis, Hb rise and decline
- Dr Tony Besarab
- Renal Academy
Post-transplant anaemia
- Dr Helio Tedesco Silva
- Renal Academy
Erythropoietin, cardiovascular biology and beyond
- Dr Pedro Aljama
- Renal Academy
C.E.R.A. has a comparable safety profile to other erythropoiesis stimulating agents (ESAs) in patients with chronic kidney disease (CKD)
- Dr Gilbert Deray
- EDTA 2008
C.E.R.A. maintains stable haemoglobin levels in dialysis patients regardless of administration route (IV or SC)
- Dr Bruce Spinowitz
- EDTA 2008
